244 related articles for article (PubMed ID: 31712669)
21. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Vinodhkumar R; Song YS; Devaki T
Biomed Pharmacother; 2008 Feb; 62(2):85-93. PubMed ID: 17644301
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
25. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F
Oncotarget; 2015 Mar; 6(7):5059-71. PubMed ID: 25671298
[TBL] [Abstract][Full Text] [Related]
26. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
[TBL] [Abstract][Full Text] [Related]
27. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Shi Y; Fu Y; Zhang X; Zhao G; Yao Y; Guo Y; Ma G; Bai S; Li H
Cancer Immunol Immunother; 2021 Jan; 70(1):61-73. PubMed ID: 32632663
[TBL] [Abstract][Full Text] [Related]
28. The BCL6-associated transcriptional co-repressor, MTA3, is selectively expressed by germinal centre B cells and lymphomas of putative germinal centre derivation.
Jaye DL; Iqbal J; Fujita N; Geigerman CM; Li S; Karanam S; Fu K; Weisenburger DD; Chan WC; Moreno CS; Wade PA
J Pathol; 2007 Sep; 213(1):106-15. PubMed ID: 17573669
[TBL] [Abstract][Full Text] [Related]
29. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
[TBL] [Abstract][Full Text] [Related]
30. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
31. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
32. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
33. Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
Kanno S; Maeda N; Tomizawa A; Yomogida S; Katoh T; Ishikawa M
Int J Oncol; 2012 May; 40(5):1391-6. PubMed ID: 22211246
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
35. Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.
Desmots F; Roussel M; Pangault C; Llamas-Gutierrez F; Pastoret C; Guiheneuf E; Le Priol J; Camara-Clayette V; Caron G; Henry C; Belaud-Rotureau MA; Godmer P; Lamy T; Jardin F; Tarte K; Ribrag V; Fest T
Clin Cancer Res; 2019 Jan; 25(2):735-746. PubMed ID: 30348636
[TBL] [Abstract][Full Text] [Related]
36. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
37. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
38. Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.
Baron BW; Zeleznik-Le N; Baron MJ; Theisler C; Huo D; Krasowski MD; Thirman MJ; Baron RM; Baron JM
Proc Natl Acad Sci U S A; 2007 May; 104(18):7449-54. PubMed ID: 17468402
[TBL] [Abstract][Full Text] [Related]
39. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
Walker SR; Nelson EA; Frank DA
Oncogene; 2007 Jan; 26(2):224-33. PubMed ID: 16819511
[TBL] [Abstract][Full Text] [Related]
40. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
